MX2012014928A - Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. - Google Patents
Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma.Info
- Publication number
- MX2012014928A MX2012014928A MX2012014928A MX2012014928A MX2012014928A MX 2012014928 A MX2012014928 A MX 2012014928A MX 2012014928 A MX2012014928 A MX 2012014928A MX 2012014928 A MX2012014928 A MX 2012014928A MX 2012014928 A MX2012014928 A MX 2012014928A
- Authority
- MX
- Mexico
- Prior art keywords
- high density
- lipid
- density lipoprotein
- formulation
- production method
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000015779 HDL Lipoproteins Human genes 0.000 title abstract 2
- 108010010234 HDL Lipoproteins Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000002632 lipids Chemical class 0.000 abstract 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 2
- 102000007592 Apolipoproteins Human genes 0.000 abstract 2
- 108010071619 Apolipoproteins Proteins 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 abstract 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una formulación de lipoproteína de alta densidad reconstituida teniendo toxicidad relativamente baja comprende una apolipoproteína tal como ApoAl o fragmento de la misma, un lípido y un detergente a un nivel que es aproximadamente 5-50% de aqué que normalmente causaría toxidad al hígado al administrar a un humano. El lípido es óptimamente fosfatidilcolina a aproximadamente 30-50 g/L y la relación molar de apolipoproteína:lípido está óptimamente en el rango de 1:40 a 1:75. La formulación es útil para tratar enfermedades o condiciones tales como enfermedad cardiovascular, hipercolesterolemia e hipocolesterolemia inclusive de síndrome coronario agudo (ACS), aterosclerosis e infarto al miocardio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35992510P | 2010-06-30 | 2010-06-30 | |
| PCT/AU2011/000819 WO2012000048A1 (en) | 2010-06-30 | 2011-06-30 | A reconstituted high density lipoprotein formulation and production method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012014928A true MX2012014928A (es) | 2013-03-22 |
Family
ID=45401226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012014928A MX2012014928A (es) | 2010-06-30 | 2011-06-30 | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8999920B2 (es) |
| EP (3) | EP2588113B1 (es) |
| JP (2) | JP5989641B2 (es) |
| KR (1) | KR101782309B1 (es) |
| CN (2) | CN105396122B (es) |
| AU (1) | AU2011274238B2 (es) |
| CA (1) | CA2803031C (es) |
| DK (2) | DK3178481T3 (es) |
| ES (2) | ES2617977T3 (es) |
| HU (2) | HUE042391T2 (es) |
| IL (1) | IL223815A (es) |
| MX (1) | MX2012014928A (es) |
| PL (2) | PL3178481T3 (es) |
| SG (1) | SG186386A1 (es) |
| TR (1) | TR201903209T4 (es) |
| TW (1) | TWI531388B (es) |
| WO (1) | WO2012000048A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2588113B1 (en) | 2010-06-30 | 2016-12-14 | CSL Limited | A reconstituted high density lipoprotein formulation and production method thereof |
| US9125943B2 (en) * | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| CN103833840A (zh) * | 2012-11-27 | 2014-06-04 | 上海复星医药（集团）股份有限公司 | 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法 |
| WO2014194362A1 (en) * | 2013-06-05 | 2014-12-11 | Csl Limited | Process for preparing apolipoprotein a-i (apo a-i) |
| ES2689333T3 (es) | 2013-08-08 | 2018-11-13 | Csl Limited | Método de eliminación de contaminantes |
| EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| KR101563403B1 (ko) * | 2013-11-05 | 2015-10-26 | 영남대학교 산학협력단 | 지방물질의 안전성 평가방법 |
| JP2017515893A (ja) | 2014-05-02 | 2017-06-15 | セレニス セラピューティクス ホールディング エスアー | Ｈｄｌ治療マーカー |
| WO2016104690A1 (ja) * | 2014-12-25 | 2016-06-30 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| US12150975B2 (en) | 2016-07-27 | 2024-11-26 | Hartis-Pharma Sa | Therapeutic combinations to treat red blood cell disorders |
| WO2018085890A1 (en) * | 2016-11-10 | 2018-05-17 | Csl Limited | Reconstituted high density lipoprotein treatment of myocardial infarction |
| MA50582A (fr) * | 2017-11-07 | 2020-09-16 | Alphacore Pharma Llc | Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés |
| AU2018396009A1 (en) * | 2017-12-28 | 2020-07-16 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
| KR102531293B1 (ko) * | 2021-12-06 | 2023-05-16 | (주) 멥스젠 | 신규한 재구축 고밀도 지단백 나노입자 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335077C (en) | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| US5652339A (en) | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| EP1438060B1 (en) | 2001-09-28 | 2015-11-11 | Esperion Therapeutics Inc. | Prevention and treatment of restenosis by local administration of drug |
| NZ537006A (en) | 2002-05-17 | 2008-01-31 | Esperion Therapeutics Inc | The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ |
| MXPA04011312A (es) * | 2002-05-17 | 2005-02-14 | Esperion Therapeutics Inc | Metodo para el tratamiento de desordenes dislipidemicos. |
| PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| US20070254832A1 (en) | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
| CN100586958C (zh) * | 2006-12-20 | 2010-02-03 | 上海莱士血液制品股份有限公司 | 高纯度载脂蛋白a-i的制备方法 |
| KR100992488B1 (ko) | 2006-12-29 | 2010-11-05 | 주식회사 녹십자 | ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법 |
| EP2520583A1 (en) | 2007-08-17 | 2012-11-07 | CSL Behring GmbH | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
| CA2780482A1 (en) * | 2008-11-17 | 2010-05-10 | Anil K. Sood | Hdl particles for delivery of nucleic acids |
| EP2588113B1 (en) | 2010-06-30 | 2016-12-14 | CSL Limited | A reconstituted high density lipoprotein formulation and production method thereof |
| SI2767546T1 (sl) | 2011-02-07 | 2019-03-29 | Cerenis Therapeutics Holding Sa | Lipoproteinski kompleksi in izdelava ter uporaba le-teh |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
-
2011
- 2011-06-30 EP EP11799979.7A patent/EP2588113B1/en active Active
- 2011-06-30 AU AU2011274238A patent/AU2011274238B2/en active Active
- 2011-06-30 WO PCT/AU2011/000819 patent/WO2012000048A1/en not_active Ceased
- 2011-06-30 DK DK16203579.4T patent/DK3178481T3/en active
- 2011-06-30 CA CA2803031A patent/CA2803031C/en active Active
- 2011-06-30 HU HUE16203579A patent/HUE042391T2/hu unknown
- 2011-06-30 EP EP16203579.4A patent/EP3178481B1/en active Active
- 2011-06-30 PL PL16203579T patent/PL3178481T3/pl unknown
- 2011-06-30 DK DK11799979.7T patent/DK2588113T3/en active
- 2011-06-30 ES ES11799979.7T patent/ES2617977T3/es active Active
- 2011-06-30 TR TR2019/03209T patent/TR201903209T4/tr unknown
- 2011-06-30 TW TW100123185A patent/TWI531388B/zh active
- 2011-06-30 KR KR1020137002377A patent/KR101782309B1/ko active Active
- 2011-06-30 PL PL11799979T patent/PL2588113T3/pl unknown
- 2011-06-30 HU HUE11799979A patent/HUE032560T2/en unknown
- 2011-06-30 MX MX2012014928A patent/MX2012014928A/es active IP Right Grant
- 2011-06-30 US US13/805,488 patent/US8999920B2/en active Active
- 2011-06-30 SG SG2012093076A patent/SG186386A1/en unknown
- 2011-06-30 CN CN201510593566.4A patent/CN105396122B/zh active Active
- 2011-06-30 EP EP18215066.4A patent/EP3492085A1/en not_active Withdrawn
- 2011-06-30 CN CN201180036314.1A patent/CN103118683B/zh active Active
- 2011-06-30 JP JP2013516907A patent/JP5989641B2/ja active Active
- 2011-06-30 ES ES16203579T patent/ES2718234T3/es active Active
-
2012
- 2012-12-23 IL IL223815A patent/IL223815A/en active IP Right Grant
-
2015
- 2015-02-27 US US14/633,880 patent/US9439946B2/en active Active
-
2016
- 2016-06-02 JP JP2016110551A patent/JP2016188226A/ja active Pending
- 2016-08-19 US US15/241,895 patent/US10335457B2/en active Active
-
2019
- 2019-06-19 US US16/445,937 patent/US11058747B2/en active Active
-
2021
- 2021-07-06 US US17/368,464 patent/US11723953B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012014928A (es) | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. | |
| NZ727849A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| EA200700924A1 (ru) | Соединения ряда дибензиламина и их производные | |
| WO2013022922A3 (en) | Fibrous structures | |
| NZ596186A (en) | Lipid compositions | |
| PH12012501846A1 (en) | Sweet flavor modifier | |
| PL2162019T3 (pl) | Kompozycja lipidowa do poprawy czynności mózgu | |
| MX2013010076A (es) | Composiciones y metodos que comprenden c16:1n7 palmitoleato. | |
| BR112012018384A2 (pt) | composição farmacêutica sólida com intensificadores e métodos de preparação da mesma. | |
| NZ631131A (en) | Reconstituted hdl formulation | |
| WO2012119781A3 (en) | Novel lipids, phospholipids, phospholipid and lipid compositions and their use | |
| MX2013002145A (es) | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma. | |
| UA108835C2 (uk) | Спосіб отримання суміші похідних лактиду | |
| RU2009138047A (ru) | Стабилизация витамина в12 | |
| CY1115573T1 (el) | Τροποποιημενα ενζυμα λεκιθινοχοληστερολικης ακυλοτρανσφερασης | |
| EA200970377A1 (ru) | Композиции фенилалкиламинокарбамата | |
| JP2017528437A5 (es) | ||
| JP2015535263A5 (es) | ||
| SI1608346T1 (sl) | Spojine za sproščanje zdravilnih učinkovin na osnovi alfa-hidroksi kislinskih estrov in postopki njihove uporabe | |
| MX2014001134A (es) | Estructuras fibrosas. | |
| WO2005092929A8 (en) | Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use | |
| DE502004008949D1 (de) | Physiologisch aktive zusammensetzung auf phosphatidylserin-basis | |
| ATE528990T1 (de) | Desinfektions- und entkeimungsmittel | |
| WO2009027785A3 (en) | 1, 3-oxazole derivatives as cetp inhibitors | |
| NO20083641L (no) | Dibenzylaminforbindelser, samt derivater derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |